Evaluation of quality of life in adult patients with MS switching from injectable therapy i.e. Interferon (Avonex, Betaseron, Extavia, Rebif) or Copaxone® (glatiramer acetate) to oral medication Tecfidera® (BG00012) and their caregivers and evaluating their physical disability, cognitive function and adherence
ID Number 13-1822Principal Investigator(s)
Aliza B Ben-Zacharia
Department(s) or Division(s)
The purpose of this study is to gather information on how the quality of life for people with relapsing Multiple Sclerosis (MS) who are taking an injectable form of medication for their MS is affected by switching to the oral medication Tecfidera.
Recruiting Patients: Yes